All In Biotech

Drug Trial Radar · NCT04001777

A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

A Phase Ib Study of Safety and Efficacy of APG-1252 in Combination With Osimertinib (AZD9291) in EGFR TKI Resistant NSCLC Patients

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

73

Actual

Start

Jul 4, 2019

Primary completion

May 27, 2025

Study completion May 27, 2025

Sponsor

Lead sponsor
Ascentage Pharma Group Inc.Industry
Sponsor type
Industry
Collaborators
Suzhou Yasheng Pharmaceutical Co., Ltd.
First posted
Jun 28, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

There are unmet medical needs in patients who resist to EGFR TKIs, especially to osimertinib; APG-1252 shows synergy with osimertinib in both osimertinib treatment naïve and resistant cell lines. This study is to explore the safety and efficacy of the combination of APG-1252 and osimertinib in 3rd generation TKI resistant patients and 3rd generation TKI treatment naïve patients.

Conditions

  • EGFR Positive Non-small Cell Lung Cancer

Interventions

  • APG-1252Drug

    Multiple dose cohorts, 30 minute IV infusion, weekly for 3 weeks of a cycle with 21days.

  • Osimertinib Mesylate TabletsDrug

    Osimertinib Mesylate Tablets 40mg/80 mg, one time a day until disease progression

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (MTD)Time frame: 21 days
  2. Recommended Phase 2 dose (RP2D)Time frame: 21 days

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Sun-Yat Sen University Cancer Center

    Guangzhou, Guangdong, China

  • Henan Provincial people's Hospital

    Zhengzhou, Henan, China

  • First Hospital of Jilin University

    Changchun, Jilin, China

  • Jilin Provincial Cancer Hospital

    Changchun, Jilin, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.